DE60140074D1 - Non-apoptotische formen des zelltods und verfahren zur modulation - Google Patents
Non-apoptotische formen des zelltods und verfahren zur modulationInfo
- Publication number
- DE60140074D1 DE60140074D1 DE60140074T DE60140074T DE60140074D1 DE 60140074 D1 DE60140074 D1 DE 60140074D1 DE 60140074 T DE60140074 T DE 60140074T DE 60140074 T DE60140074 T DE 60140074T DE 60140074 D1 DE60140074 D1 DE 60140074D1
- Authority
- DE
- Germany
- Prior art keywords
- paraptosis
- cell death
- methods
- modulation
- caspase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96466—Cysteine endopeptidases (3.4.22)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25602300P | 2000-12-14 | 2000-12-14 | |
US25669400P | 2000-12-19 | 2000-12-19 | |
PCT/US2001/048261 WO2002054066A2 (en) | 2000-12-14 | 2001-12-13 | Non-apoptotic forms of cell death and methods of modulation |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60140074D1 true DE60140074D1 (de) | 2009-11-12 |
Family
ID=26945108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60140074T Expired - Lifetime DE60140074D1 (de) | 2000-12-14 | 2001-12-13 | Non-apoptotische formen des zelltods und verfahren zur modulation |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090263852A1 (de) |
EP (1) | EP1342085B1 (de) |
AT (1) | ATE444488T1 (de) |
AU (1) | AU2002248180A1 (de) |
DE (1) | DE60140074D1 (de) |
WO (1) | WO2002054066A2 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101086533B1 (ko) | 2002-05-24 | 2011-11-23 | 쉐링 코포레이션 | 중화 사람 항-igfr 항체, 이를 제조하는 방법 및 이를 포함하는 조성물 |
FI20030130A0 (fi) | 2003-01-29 | 2003-01-29 | Licentia Oy | Seulontamenetelmä |
EP1694850B1 (de) | 2003-11-12 | 2011-06-29 | Schering Corporation | Plasmidsystem zur expression mehrerer gene |
PT1828249E (pt) | 2004-12-03 | 2011-02-25 | Schering Corp | Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r |
US20090110673A1 (en) * | 2006-05-25 | 2009-04-30 | The University Of Chicago | Methods of reducing cell death following hypoxia / reoxygenation |
WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
WO2014197638A2 (en) | 2013-06-05 | 2014-12-11 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
EP3384908B1 (de) * | 2013-12-02 | 2020-09-30 | The Trustees of Columbia University in the City of New York | Modulation von ferroptose und behandlung von exzitotoxischen störungen |
WO2015134877A1 (en) * | 2014-03-07 | 2015-09-11 | Bellicum Pharmaceuticals, Inc. | Caspase polypeptides having modified activity and uses thereof |
AU2015341481C1 (en) | 2014-11-03 | 2021-09-16 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) | T cell receptors directed against Bob1 and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63218681A (ja) * | 1987-03-09 | 1988-09-12 | Mitsubishi Kasei Corp | オリゴマイシンe |
US5268164A (en) * | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
US5958872A (en) * | 1996-04-01 | 1999-09-28 | Apoptosis Technology, Inc. | Active survival domains of IGF-IR and methods of use |
US5752515A (en) * | 1996-08-21 | 1998-05-19 | Brigham & Women's Hospital | Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier |
US6063758A (en) * | 1997-07-09 | 2000-05-16 | Advanced Targeting Systems, Inc. | Substance P-Saporin (SP-SAP) conjugates and methods of use thereof |
WO2000021550A2 (en) * | 1998-10-13 | 2000-04-20 | President And Fellows Of Harvard College | Methods and compositions for treating neurodegenerative diseases |
US20040072888A1 (en) * | 1999-08-19 | 2004-04-15 | Bennett Brydon L. | Methods for treating inflammatory conditions or inhibiting JNK |
US7119114B1 (en) * | 1999-08-19 | 2006-10-10 | Signal Pharmaceuticals, Llc | Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto |
WO2001074769A1 (en) * | 2000-03-27 | 2001-10-11 | Applied Research Systems Ars Holding N.V. | Pharmaceutically active pyrrolidine derivatives as bax inhibitors |
CN1604776A (zh) * | 2001-10-16 | 2005-04-06 | 记忆药物公司 | 作为用于治疗神经病综合症的pde-4抑制剂的4-(4-烷氧基-3-羟基苯基)-2-吡咯烷酮衍生物 |
US6994981B2 (en) * | 2002-02-19 | 2006-02-07 | The Buck Institute | Modulators of paraptosis and related methods |
-
2001
- 2001-12-13 AT AT01997059T patent/ATE444488T1/de not_active IP Right Cessation
- 2001-12-13 EP EP01997059A patent/EP1342085B1/de not_active Expired - Lifetime
- 2001-12-13 DE DE60140074T patent/DE60140074D1/de not_active Expired - Lifetime
- 2001-12-13 WO PCT/US2001/048261 patent/WO2002054066A2/en not_active Application Discontinuation
- 2001-12-13 AU AU2002248180A patent/AU2002248180A1/en not_active Abandoned
-
2009
- 2009-02-18 US US12/388,431 patent/US20090263852A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002054066A2 (en) | 2002-07-11 |
EP1342085B1 (de) | 2009-09-30 |
EP1342085A2 (de) | 2003-09-10 |
US20090263852A1 (en) | 2009-10-22 |
ATE444488T1 (de) | 2009-10-15 |
WO2002054066A3 (en) | 2002-10-31 |
AU2002248180A1 (en) | 2002-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69815090D1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
DE60027732D1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
MX9801093A (es) | Inhibidores de la proteinasa c para el tratamiento de enfermedades relacionadas con la sobreproduccion de colagena. | |
ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
ATE402698T1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
ATE519862T1 (de) | Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs | |
DE60121808D1 (de) | Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen | |
ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
ATE538781T1 (de) | Neue verwendung von peptidverbindungen zur behandlung von dyskinesie | |
ATE224713T1 (de) | Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression | |
ATE444488T1 (de) | Non-apoptotische formen des zelltods und verfahren zur modulation | |
ATE454161T1 (de) | Verwendung von fviia oder fviiai zur behandlung von endothelialer fehlfunktion bzw zur inhibierung der angiogenese | |
ATE542536T1 (de) | 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen | |
ATE461697T1 (de) | Phospholipidderivate von valproinsäure und ihre kombinationen | |
DE60222745D1 (de) | Verwendung von neurofilamentproteinen zur behandlung von tumoren | |
ATE394124T1 (de) | Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums | |
ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
ATE353667T1 (de) | Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges | |
NO20010389L (no) | Modulering av multippel linje kinase proteiner | |
DE69918972D1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
ATE298246T1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
ATE288498T1 (de) | Methoden zur inhibierung von helicobacter pylori | |
ATE339208T1 (de) | Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs | |
DE60137721D1 (de) | Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs | |
DE60220825D1 (de) | Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |